nach oben

Journal of Neuro-Oncology

Erschienen in:

11.01.2017 | Clinical Study

Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods

verfasst von: Kavitha Nutakki, James W. Varni, Sheila Steinbrenner, Claire B. Draucker, Nancy L. Swigonski

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Health-related quality of life (HRQOL) is arguably one of the most important measures in evaluating effectiveness of clinical treatments. At present, there is no disease-specific outcome measure to assess the HRQOL of children, adolescents and young adults with Neurofibromatosis Type 1 (NF1). This study aimed to develop the items and support the content validity for the Pediatric Quality of Life Inventory™ (PedsQL™) NF1 Module for children, adolescents and young adults. The iterative process included multiphase qualitative methods including a literature review, survey of expert opinions, semi-structured interviews, cognitive interviews and pilot testing. Fifteen domains were derived from the qualitative methods, with content saturation achieved, resulting in 115 items. The domains include skin, pain, pain impact, pain management, cognitive functioning, speech, fine motor, balance, vision, perceived physical appearance, communication, worry, treatment, medicines and gastrointestinal symptoms. This study is limited because all participants are recruited from a single-site. Qualitative methods support the content validity for the PedsQL™ NF1 Module for children, adolescents and young adults. The PedsQL™ NF1 Module is now undergoing national multisite field testing for the psychometric validation of the instrument development.

Williams VC et al (2009) Neurofibromatosis type 1 revisited. Pediatrics 123(1):124–133CrossRefPubMed

Lu-Emerson C, Plotkin SR (2009) The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6(2):E47–E53PubMed

Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89(1):1–6CrossRefPubMed

Friedman JM (2002) Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 17(8):548–554 (discussion 571–572, 646–651) CrossRefPubMed

Wimmer K (2005) Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome. Wien Med Wochenschr 155(11–12):273–280CrossRefPubMed

Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12(1):1–11CrossRefPubMed

Anderson JL, Gutmann DH (2015) Neurofibromatosis type 1. Handb Clin Neurol 132:75–86CrossRefPubMed

Evans DG et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311–314CrossRefPubMedPubMedCentral

Ferner RE, Gutmann DH (2013) Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 115:939–955CrossRefPubMed

10.

Sabatini C et al (2015) Treatment of neurofibromatosis type 1. Curr Treat Options Neurol 17(6):355CrossRefPubMed

11.

Karajannis MA, Ferner RE (2015) Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr 27(1):26–33CrossRefPubMedPubMedCentral

12.

Guyatt GH et al (1989) Measuring quality of life in clinical trials: a taxonomy and review. Cmaj 140(12):1441–1448PubMedPubMedCentral

13.

Vranceanu AM et al (2015) Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol 122(2):219–228CrossRefPubMed

14.

Vranceanu AM et al (2013) Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 114(3):257–262CrossRefPubMed

15.

Wells GA et al (2011) Validity of quality of life measurement tools—from generic to disease-specific. J Rheumatol Suppl 88:2–6CrossRefPubMed

16.

Nutakki K et al (2013) Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes 11:21CrossRefPubMedPubMedCentral

17.

Lasch KE et al (2010) PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 19(8):1087–1096CrossRefPubMedPubMedCentral

18.

Brod M, Tesler LE, Christensen TL (2009) Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res 18(9):1263–1278CrossRefPubMed

19.

Irwin DE et al (2009) Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes 7:3CrossRefPubMedPubMedCentral

20.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79CrossRefPubMedCentral

21.

Varni JW et al (2012) PedsQL gastrointestinal symptoms module item development: qualitative methods. J Pediatr Gastroenterol Nutr 54(5):664–671CrossRefPubMed

22.

Panepinto JA, Torres S, Varni JW (2012) Development of the PedsQL sickle cell disease module items: qualitative methods. Qual Life Res 21(2):341–357CrossRefPubMed

23.

Franciosi JP et al (2012) Development of the pediatric quality of life inventory eosinophilic esophagitis module items: qualitative methods. BMC Gastroenterol 12:135CrossRefPubMedPubMedCentral

24.

Varni JW et al (2006) The PedsQL in pediatric cerebral palsy: reliability, validity, and sensitivity of the generic core scales and cerebral palsy module. Dev Med Child Neurol 48(6):442–449CrossRefPubMed

25.

Varni JW et al (2003) The PedsQL in type 1 and type 2 diabetes: reliability and validity of the pediatric quality of life inventory generic core scales and type 1 diabetes module. Diabetes Care 26(3):631–637CrossRefPubMed

26.

Varni JW et al (2002) The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 94(7):2090–2106CrossRefPubMed

27.

Varni JW et al (2002) The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 46(3):714–725CrossRefPubMed

28.

Varni JW et al (2004) The PedsQL in pediatric asthma: reliability and validity of the Pediatric Quality of Life Inventory generic core scales and asthma module. J Behav Med 27(3):297–318CrossRefPubMed

29.

Goldstein SL et al (2008) Measuring health-related quality of life in children with ESRD: performance of the generic and ESRD-specific instrument of the Pediatric Quality of Life Inventory (PedsQL). Am J Kidney Dis 51(2):285–297CrossRefPubMed

30.

Palmer SN et al (2007) The PedsQL Brain Tumor Module: initial reliability and validity. Pediatr Blood Cancer 49(3):287–293CrossRefPubMed

31.

Weissberg-Benchell J et al (2010) Pediatric health-related quality of life: Feasibility, reliability and validity of the PedsQL transplant module. Am J Transplant 10(7):1677–1685CrossRefPubMed

32.

Follansbee-Junger KW et al (2016) Development of the PedsQL Epilepsy Module: Focus group and cognitive interviews. Epilepsy Behav 62:115–120CrossRefPubMed

33.

Varni JW et al (2013) Content validity of the PedsQL 3.2 Diabetes Module in newly diagnosed patients with Type 1 diabetes mellitus ages 8–45. Qual Life Res 22(8):2169–2181CrossRefPubMed

34.

Varni JW The PedsQL measurement model for the pediatric quality of life inventory. PedsQL 1998–2016 [cited 2016 May 27]. http://www.pedsql.org/

35.

PROMIS Measures cited 2016. http://www.nihpromis.org/measures/selectinginstrument

36.

NeuroQOL 2013 cited 2016. http://www.neuroqol.org/WhatandWhy/BankDevelopment/Pages/default.aspx

37.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483CrossRefPubMed

38.

Chren MM (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30(2):231–236 (xiii) CrossRefPubMed

39.

Lewis-Jones MS, Finlay AY (1995) The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 132(6):942–949CrossRefPubMed

40.

Hogikyan ND, Sethuraman G (1999) Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 13(4):557–569CrossRefPubMed

41.

Rinkel RN et al (2008) Speech Handicap Index in patients with oral and pharyngeal cancer: better understanding of patients’ complaints. Head Neck 30(7):868–874CrossRefPubMed

42.

Paz SH et al (2013) Development of a vision-targeted health-related quality of life item measure. Qual Life Res 22(9):2477–2487CrossRefPubMed

43.

DeWalt DA et al (2007) Evaluation of item candidates: the PROMIS qualitative item review. Med Care 45(5 Suppl 1):S12–S21CrossRefPubMedPubMedCentral

44.

Varni JW et al (2010) PROMIS Pediatric Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. J Pain 11(11):1109–1119CrossRefPubMedPubMedCentral

45.

Irwin DE et al (2010) Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res 19(4):585–594CrossRefPubMedPubMedCentral

46.

Yeatts KB et al (2010) Construction of the Pediatric Asthma Impact Scale (PAIS) for the Patient-Reported Outcomes Measurement Information System (PROMIS). J Asthma 47(3):295–302CrossRefPubMedPubMedCentral

47.

Irwin DE et al (2010) An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales. Qual Life Res 19(4):595–607CrossRefPubMedPubMedCentral

48.

Varni JW, Thompson KL, Hanson V (1987) The Varni/Thompson Pediatric Pain Questionnaire. I. Chronic musculoskeletal pain in juvenile rheumatoid arthritis. Pain 28(1):27–38CrossRefPubMed

49.

Varni JW, Limbers CA, Burwinkle TM (2007) Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 5:43CrossRefPubMedPubMedCentral

50.

Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation variability. Field Methods 18(1):59–82CrossRef

Titel: Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods
verfasst von: Kavitha Nutakki
James W. Varni
Sheila Steinbrenner
Claire B. Draucker
Nancy L. Swigonski
Publikationsdatum: 11.01.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2351-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis

Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database

Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma

Assessment of vascularity in glioblastoma and its implications on patient outcomes

11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma

Functional analysis of KIF20A, a potential immunotherapeutic target for glioma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie